Journal: NPJ Precision Oncology

Article Title: Multi-omics profiling reveals tumor microenvironment characteristics linked to immunotherapy response and prognosis in non-small cell lung cancer

doi: 10.1038/s41698-026-01474-2

Figure Lengend Snippet: A Identification of four celltypes in the LLC TME by scRNA-seq. B Anti-SPP1 therapy increases all immune subsets, decreases non-immune cells. C Subclustering of T/NK cells. D GO enrichment analysis of genes highly expressed in CD8 + T cells at different groups (control vs. anti-SPP1). E Anti-SPP1 therapy decreases M2-like macrophage proportion. F Immunofluorescence indicated increased CD8 + T infiltration with concurrent M2 reduction post-treatment.

Article Snippet: Five days post-inoculation, mice with palpable tumors were randomly assigned to four treatment groups ( n = 4 per group) using a random number table : Control (PBS) , Anti-PD-1 (clone RMP1-14, Bio X Cell, #BE0146) , Anti-SPP1 (anti-mouse osteopontin antibody, clone 103D6, MCE), and Anti-SPP1 combined with Anti-PD-1.

Techniques: Control, Immunofluorescence